Matthew Krantz, MD

Matthew Krantz, MD, from Vanderbilt University Medical Center

Articles by Matthew Krantz, MD

HCPLive Five at AAAAI 2026

ByMatthew Krantz, MD,Sayantani Sindher, MD,Jose Clemente, PhD,Joseph K. Han,Adil Adatia, MD

March 11th 2026

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

HLA-A*32:01 Carrier Screening Feasibility Before Lamotrigine, With Matthew Krantz, MD

ByMatthew Krantz, MD

February 28th 2026

HLA-A*32:01 carrier screening may identify patients at elevated risk for lamotrigine-induced eosinophilia and systemic symptoms, Krantz says at AAAAI 2026.

HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD

ByMatthew Krantz, MD

February 28th 2026

Prospective case-control data presented at AAAI 2026 demonstrate a 12-fold increased odds of DRESS among lamotrigine-treated HLA-A*32:01 carriers.

Matthew Krantz, MD

Articles by Matthew Krantz, MD

HCPLive Five at AAAAI 2026

HLA-A*32:01 Carrier Screening Feasibility Before Lamotrigine, With Matthew Krantz, MD

HLA-A*32:01 Linked to Lamotrigine DRESS Risk, With Matthew Krantz, MD

Latest Updated Articles

Trending on HCPLive

AXIOMATIC-TKR: Milvexian Decouples Thrombosis, Hemostasis in DVT

SYMPHONY-PE: Early Thrombectomy Improves Pulmonary Embolism Outcomes

REMAIN-1: Improved GLP-1-Induced Weight Loss Retention With Revita DMR System

FDA Grants Obinutuzumab Priority Review as Primary Membranous Nephropathy’s Potential First Therapy

ABCs in Dermatology: Updates in Psoriasis Management for 2026